Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5374898 | 0.83 | MAOB (0.52) | ESR1ESR2RAB9A | |
| SCHEMBL13070033 | 0.81 | ESR1 (0.50) | ESR1ESR2EPHX2RAB9A | |
| SCHEMBL5378603 | 0.78 | ESR1 (0.76) | ESR1ESR2 | |
| SCHEMBL13069910 | 0.78 | ESR1 (0.53) | ESR1ESR2DRD2HTR2AHTR7 | |
| SCHEMBL14081509 | 0.78 | ESR1 (0.53) | ESR1ESR2RAB9A | |
| SCHEMBL5365388 | 0.77 | LSS (0.44) | ESR1ESR2DRD2HTR2AHTR6 | |
| SCHEMBL13588378 | 0.77 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL13069526 | 0.77 | ESR1 (0.49) | ESR1ESR2DRD2 | |
| SCHEMBL5368893 | 0.76 | LSS (0.46) | ESR1ESR2DRD2HTR2AHTR6 | |
| SCHEMBL8801411 | 0.76 | ESR1 (0.50) | ESR1ESR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796665-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | LIPA, APOB, LCAT | ESR1 4422/4885ESR2 2327/4885DRD2 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.